Objectives: It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining ,1 HIV RNA copy/mL. We therefore investigated the effect of residual viraemia on virological rebound.
Introduction
The current goal of antiretroviral therapy is to attain plasma HIV RNA loads of ,50 copies/mL, and to maintain these for as long as possible, in patients on their first-line regimen and in those experiencing virological failure. 1 -3 A threshold of 50 copies/mL is used because it is reliable at any disease stage and to prevent the selection of drug-resistant HIV variants.
Furthermore, there is a lack of evidence for resistance evolution in patients who have viral loads below the 50 copies/mL threshold and that intensification in patients with this level of viraemia does result in any further decline in viral load.
It has been demonstrated that most of the patients with plasma HIV RNA loads of ,50 copies/mL have some degree of residual viraemia in plasma or in cell reservoirs, 4, 5 and it is currently debated as to whether patients with residual viraemia (1 -49 HIV RNA copies/mL) are at higher risk of virological failure than aviraemic patients (,1 copy/mL). Clarifying this question should help define the best management strategy for patients considered to be responders (HIV RNA ,50 copies/mL according to the current guidelines).
Furthermore, the magnitude of the virological response below 50 copies/mL might influence the degree of the immune response.
The aim of this study was to investigate the effect of residual viraemia on virological rebound. The study was designed on the basis of the hypothesis that patients with residual viraemia are at higher risk of rebound than those attaining plasma levels of ,1 HIV RNA copy/mL in plasma. 
Methods

Virology
At the Department of Infectious Diseases of the San Raffaele Scientific Institute, plasma HIV RNA was quantified on the basis of the branched DNA Versant HIV-1 RNA 3.0 Assay (Siemens Diagnostics, Terrytown, NY, USA; limit of quantification 50 HIV RNA copies/mL) up to February 2009. The branched DNA assay gives two possible outputs: a quantitative result for levels of HIV RNA ≥50 copies/mL; and a qualitative result ('undetectable') if HIV RNA is below the limit of quantification. Since March 2009, all patients have been routinely tested using the kinetic PCR molecular system (kPCR) (Versant HIV-1 RNA kPCR 1.0; Siemens Diagnostics). 6, 7 Plasma samples were tested in accordance with the manufacturer's instructions. The kPCR assay gives three possible outputs: a quantitative result for HIV RNA levels .37 copies/mL; a semi-quantitative result when the amount of HIV RNA is between 1 and 37 copies/mL; and a qualitative result ('undetectable') if HIV RNA is below the limit of quantification (1 copy/mL).
Patient selection
The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Data were collected as part of routine clinical practice. At each visit, patients provided written informed consent to give their clinical and biological data to the Department of Infectious Diseases of the San Raffaele Scientific Institute.
HIV-infected patients over 18 years of age were included in this analysis if their last four consecutive HIV RNA values were below 50 copies/mL, that is, two consecutive HIV RNA viral loads (VLs) of ,50 copies/mL as tested by Versant bDNA followed by two consecutive HIV RNA VLs of ,50 copies/mL by Versant kPCR.
Two patient groups were identified on the basis of the kPCR results: patients with an HIV RNA load of ,1 copy/mL confirmed in two consecutive samples (group A); and patients with residual viraemia, defined as an HIV RNA load of ,1 copy/mL in one sample and not in the other or two HIV RNA values of between 1 and 49 copies/mL (group B).
Adherence and health status
Adherence and health status were assessed by means of a self-report questionnaire 8, 9 and primarily evaluated by means of a visual analogue scale (VAS). In addition to completing the VAS, patients were also asked to answer a few simple questions: 'Have you missed any dose over the last week?' (possible responses: never, yes); 'If yes, please specify how many doses you missed' (possible responses: one, two, three, more than three); and 'Have you ever spontaneously stopped treatment for more than 2 days in the last 6 months?' (possible responses: never, yes).
Statistical analysis
Combination regimens were grouped into five classes; nucleoside reverse transcriptase inhibitor (NRTI)-based, non-NRTI (NNRTI)-based, unboosted protease inhibitor (PI)-based, ritonavir boosted PI (PI/r)-based and new drugs-based. The new drugs-based regimens were those containing at least one of enfuvirtide, raltegravir or maraviroc. The detectability ratio (DR) was calculated as the number of HIV RNA measurements of .50 copies/mL divided by the number of HIV RNA values available from the start of antiretroviral therapy to the first kPCR test. Baseline was defined as the date the patients were first tested by Versant kPCR, and virological rebound was defined as two consecutive HIV RNA values of .50 copies/mL after baseline. Eligible patients were prospectively followed, and the outcome measure was the time to virological rebound. The characteristics of the subjects in groups A and B were compared using Wilcoxon's rank-sum test and the x 2 test, as appropriate. Time to virological rebound (the primary analysis) was evaluated using the Kaplan-Meier method, and the curves of groups A and B were compared by the log-rank test. In this analysis, the patients who changed any of the antiretroviral drugs in their regimen during follow-up while their HIV RNA load was ,50 copies/mL were censored at the time of the switch.
A sensitivity analysis was performed considering as outcome ('failure') both the virological rebound and the modification of the baseline therapy for any reason (thus including all the modifications due to reasons, other than virological failure, that occurred while the patients had ,50 HIV RNA copies/mL).
Linear regression was applied to estimate the mean annual change (slope) of CD4+ cell counts for each patient; current CD4+ and nadir CD4+ were included in the model to obtain adjusted estimates.
The Cox proportional hazard model was used in a multivariable analysis to calculate the risk of virological rebound during the follow-up; the hazard ratios and their 95% confidence intervals were estimated. No statistical method was used for the selection of the variables for the multivariable analysis. Demographic characteristics, potential confounders known to be clinically relevant to time to virological failure and factors with a P value ≤0.10 at univariate analysis were included in the final model.
All of the statistical tests were two-sided at the 5% level, and were made using SAS Software (release 9.2; SAS Institute).
Results
A total of 739 patients fulfilled the inclusion criteria and were included in the analysis; 446 (60.4%) had two consecutive HIV RNA values of ,1 copy/mL by kPCR (group A) and 293 (39.6%) had residual viraemia by kPCR (group B). Of the patients with residual viraemia, 73 had two consecutive VLs of between 1 and 49 copies/mL, and 220 had one HIV RNA value of ,1 copy/mL and the other between 1 and 49 copies/mL.
The time interval [median (Q1, Q3)] between the first bDNA HIV RNA ,50 copies/mL and the second kPCR HIV RNA ,50 copies/mL was 317 (265, 362) days [group A 317 (265, 359) days; group B 318 (263, 364) days; P ¼ 0.438]. Table 1 shows the baseline characteristics of the patients; the only significant differences between the two groups were gender (P ¼ 0.012), DR (P,0.0001), ongoing regimen (P ¼ 0.017) and type of ongoing regimen (P ¼ 0.001).
After After virological failure, treatment was changed in 7/10 patients. The results of resistance testing at failure were not available in six patients (one patient was lost to follow-up and viraemia at ,1000 copies/mL was found in the other five). In the four cases for which resistance testing was available, drug-resistant HIV variants were always detected.
Survival analysis (Figure 1a) showed that the probability of virological rebound was similar in the two groups (log-rank test P ¼ 0.231).
Gianotti et al. Wilcoxon rank-sum test. c Most frequently used antiretroviral combinations (other combinations used in ,2% of study patients).
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In the sensitivity analysis, failures were equally distributed over time (log-rank test P ¼ 0.625).
Multivariable analysis (Figure 1b) showed that none of the following characteristics was independently associated with the risk of virological rebound; gender, age, HIV risk factor, duration of antiretroviral therapy, history of AIDS-defining illness, nadir CD4+ cell counts, current CD4+ cell counts, type or duration of baseline antiretroviral therapy, DR, self-reported adherence or health status, or residual viraemia versus attaining a VL of ,1 HIV RNA copy/mL.
The adjusted CD4+ change [median (Q1, Q3)] in group A was +21.2 (22.5, 53.2) cells/mm 3 per year and +14.3 (27.7, 43.9) cells/mm 3 per year in group B (A versus B P ¼ 0.036).
Discussion
This is the first clinical study to investigate the effect of residual viraemia on virological outcomes in HIV-infected patients who were virologically suppressed according to the current guidelines.
The results confirmed that residual viraemia is common in patients whose HIV RNA levels are persistently ,50 copies/mL (four consecutive samples), but also showed that residual viraemia does not favour virological breakthrough over 1 year of follow-up and that virological rebound is very uncommon in this clinical setting. The frequency of virological rebound was higher among patients with residual viraemia. The fact that this difference was not statistically significant was possibly due to the very low rate of events in both groups.
The two groups were remarkably similar at baseline. The only statistical differences were gender (probably not clinically meaningful), the DR (in some respects this is how the groups are defined, so it would be surprising if they were not different) and regimen. As none of these variables was independently associated with virological breakthrough, it is likely that these baseline differences had limited impact on the virological outcome.
Although we did not find that residual viraemia plays a role in virological breakthrough, we did observe a small but statistically significant improvement in CD4+ cell recovery in those patients whose baseline VLs were consistently ,1 HIV RNA copy/mL. This suggests that there is a gradient in the extent of the immune response to effective antiretroviral therapy, which is driven by the magnitude of the virological response.
We found a higher proportion of patients with a VL of ,1 HIV RNA copy/mL than in previous studies; 4,5 the most likely reason for such a discrepancy is the different assays used to quantify HIV RNA.
The lack of association between residual viraemia and virological rebound lends some support to the hypothesis that residual viraemia arises from the occasional activation of latently infected cells (with consequent virus expression) rather than ongoing viral replication.
The results of this study can be applied to patients with HIV RNA levels persistently ,50 copies/mL (at least four consecutive samples). A limitation of this study is the relatively short follow-up; we cannot exclude that an effect of residual viraemia on virological breakthrough will be seen only after some years of observation.
In conclusion, the rate of virological rebound in patients with VLs of ,50 HIV RNA copies/mL is very low, and residual viraemia (as measured by kPCR) is not associated with virological rebound over 1 year of follow-up. Our results do not suggest that the threshold of 50 HIV RNA copies/mL should be lowered in order to define the virological response to antiretroviral therapy; however, we did find a small but statistically significant improvement in CD4+ cell recovery in patients attaining a VL of ,1 HIV RNA copy/mL, compared with those with residual viraemia.
